NEW YORK - Immunocore yakati neMuvhuro ichatengesa migove 3,733,333 muchibvumirano chemari yekudyara mari yeprivate equity (PIPE) icho chinotarisirwa kuunganidza $140 miriyoni.
Pasi pechibvumirano ichi, Immunocore ichatengesa masheya ayo akajairika nemasheya asiri ekuvhota nemadhora makumi matatu nemanomwe ($37.50) pachikamu chimwe nechimwe. Varipo mukambani iyi vanoisa mari vanosanganisira RTW Investments, Rock Springs Capital neGeneral Atlantic. Chibvumirano chePIPE chinotarisirwa kupera musi wa20 Chikunguru.
Kambani iyi ichashandisa mari yakawanikwa iyi kutsigira zvirongwa zvayo zvekurapa kenza nezvirwere zvinotapukira, kusanganisira kugadzira mushonga wayo unotungamira wekurapa kenza, Kimmtrak (tebentafusp-tebn), kurapa HLA-A*02:01 ganda rakanaka uye uveal melanoma. Mari iyi, pamwe chete nemari inobva kuKimmtrak, inotarisirwa kutsigira mashandiro eImmunocore kusvika mugore ra2025.
Gore rino, Kimmtrak yakatenderwa kushandiswa kuvarwere vane HLA-A*02:01 positive unresectable kana metastatic uveal melanoma muUS, Europe neUK, pakati pedzimwe nyika. Immunocore inoramba ichidzidza mushonga uyu muchidzidzo chePhase I/II muHLA-A*02:01-positive cutaneous melanoma.
Immunocore iri kugadzirawo mimwe mishonga mina yekenza, kusanganisira mimwe mishonga miviri yeT-cell receptor mukuyedzwa kwePhase I/II mumatumbu akasimba. Mumwe wemishonga uri kugadzirwa kune varwere vane HLA-A*02:01-positive uye MAGE-A4-positive, uye mumwe wacho uri kunangana neHLA-A*02:01 uye PRAME-positive. Kambani iyi inewo miviri isina kutaurwa pachena yekenza mukuvandudzwa kwe preclinical.
Mutemo weKuchengetedza Ruzivo.mitemo neMamiriro. Kodzero © 2022 GenomeWeb, chikamu chebhizinesi cheCrain Communications. Kodzero dzose dzakachengetedzwa.